RBW Consulting

rbwconsulting.com

RBW Consulting is a specialist Pharmaceutical, HR, Medical Devices, Data Science and IT Recruitment company that has teams of specialist consultants that offer a truly global coverage to our clients and candidates. Whether you are a candidate or a client of ours, you can always expect to receive the very best service.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed | February 15, 2021

news image

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More

Business Insights

THERAPEUTICSMD AND EW HEALTHCARE PARTNERS ANNOUNCE DEFINITIVE AGREEMENT FOR EW HEALTHCARE PARTNERS TO ACQUIRE THERAPEUTICSMD

TherapeuticsMD, Inc | June 01, 2022

news image

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding sh...

Read More

Business Insights

SIGNET HEALTHCARE PARTNERS COMPLETES GROWTH EQUITY INVESTMENT IN JUNO PHARMACEUTICALS CORP

Juno Pharmaceuticals | February 25, 2022

news image

Juno Pharmaceuticals Corp a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth. “We are very pleased with the opportunity to partner with the Juno management te...

Read More

Pharma Tech

RANOK THERAPEUTICS ANNOUNCES AGREEMENT WITH PFIZER ON TARGETED PROTEIN DEGRADATION

Ranok Therapeutics | November 30, 2021

news image

Ranok Therapeutics Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target. Terms of the agreement were not disclosed. Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP™ (Chaperone-mediated Protein Deg...

Read More
news image

Research

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed | February 15, 2021

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More
news image

Business Insights

THERAPEUTICSMD AND EW HEALTHCARE PARTNERS ANNOUNCE DEFINITIVE AGREEMENT FOR EW HEALTHCARE PARTNERS TO ACQUIRE THERAPEUTICSMD

TherapeuticsMD, Inc | June 01, 2022

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding sh...

Read More
news image

Business Insights

SIGNET HEALTHCARE PARTNERS COMPLETES GROWTH EQUITY INVESTMENT IN JUNO PHARMACEUTICALS CORP

Juno Pharmaceuticals | February 25, 2022

Juno Pharmaceuticals Corp a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth. “We are very pleased with the opportunity to partner with the Juno management te...

Read More
news image

Pharma Tech

RANOK THERAPEUTICS ANNOUNCES AGREEMENT WITH PFIZER ON TARGETED PROTEIN DEGRADATION

Ranok Therapeutics | November 30, 2021

Ranok Therapeutics Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, announced an agreement with Pfizer Inc. to apply and evaluate Ranok’s CHAMP™ platform technology on an undisclosed cancer target. Terms of the agreement were not disclosed. Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP™ (Chaperone-mediated Protein Deg...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us